

Ralph Pantophlet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7415489/publications.pdf>

Version: 2024-02-01

50
papers

4,218
citations

218677

26
h-index

189892

50
g-index

57
all docs

57
docs citations

57
times ranked

3953
citing authors

#	ARTICLE	IF	CITATIONS
1	Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. <i>Science</i> , 2001, 293, 1155-1159.	12.6	870
2	The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of 2 Mannose Residues on the Outer Face of gp120. <i>Journal of Virology</i> , 2002, 76, 7306-7321.	3.4	664
3	GP120: Target for Neutralizing HIV-1 Antibodies. <i>Annual Review of Immunology</i> , 2006, 24, 739-769.	21.8	404
4	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2003, 77, 642-658.	3.4	237
5	Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. <i>Journal of Virology</i> , 2007, 81, 6548-6562.	3.4	181
6	Differential Roles of CD14 and Toll-like Receptors 4 and 2 in Murine <i>Acinetobacter</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 122-129.	5.6	166
7	Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design. <i>Journal of Virology</i> , 2003, 77, 5889-5901.	3.4	126
8	Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds. <i>Chemistry and Biology</i> , 2010, 17, 357-370.	6.0	125
9	A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. <i>Journal of Virology</i> , 2008, 82, 6359-6368.	3.4	112
10	Comparing Antigenicity and Immunogenicity of Engineered gp120. <i>Journal of Virology</i> , 2005, 79, 12148-12163.	3.4	96
11	A Dominant Role for CD8 + -T-Lymphocyte Selection in Simian Immunodeficiency Virus Sequence Variation. <i>Journal of Virology</i> , 2004, 78, 14012-14022.	3.4	89
12	Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization. <i>Journal of Molecular Biology</i> , 2008, 375, 969-978.	4.2	71
13	Structure of a High-affinity Mimotope Peptide Bound to HIV-1-neutralizing Antibody b12 Explains its Inability to Elicit gp120 Cross-reactive Antibodies. <i>Journal of Molecular Biology</i> , 2007, 369, 696-709.	4.2	65
14	Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. <i>Virology</i> , 2007, 364, 441-453.	2.4	65
15	The Carbohydrate Epitope of the Neutralizing Anti-HIV-1 Antibody 2G12. <i>Advances in Experimental Medicine and Biology</i> , 2003, 535, 205-218.	1.6	65
16	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	4.0	65
17	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	6.0	64
18	Structural and Serological Characterisation of Two O-Specific Polysaccharides of <i>Acinetobacter</i> . <i>FEBS Journal</i> , 1996, 239, 602-610.	0.2	56

#	ARTICLE	IF	CITATIONS
19	Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. <i>Virology</i> , 2008, 381, 251-260.	2.4	54
20	Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site. <i>Journal of Virology</i> , 2011, 85, 9039-9050.	3.4	49
21	Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. <i>Trends in Molecular Medicine</i> , 2003, 9, 468-473.	6.7	43
22	O-Antigen Diversity among <i>Acinetobacter baumannii</i> Strains from the Czech Republic and Northwestern Europe, as Determined by Lipopolysaccharide-Specific Monoclonal Antibodies. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2576-2580.	3.9	34
23	A Bacterial Lipooligosaccharide that Naturally Mimics the Epitope of the HIV-Neutralizing Antibody 2G12 as a Template for Vaccine Design. <i>Chemistry and Biology</i> , 2012, 19, 254-263.	6.0	33
24	Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. <i>Nature Communications</i> , 2017, 8, 1601.	12.8	33
25	Structural and Serological Characterisation of the O-Antigenic Polysaccharide of the Lipopolysaccharide from <i>Acinetobacter Junii</i> Strain 65. <i>FEBS Journal</i> , 1997, 245, 477-481.	0.2	31
26	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849.	4.0	31
27	Specificity of Rabbit Antisera against Lipopolysaccharide of <i>Acinetobacter</i> . <i>Journal of Clinical Microbiology</i> , 1998, 36, 1245-1250.	3.9	28
28	Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus III _B Strain Isolated from an Accidentally Infected Laboratory Worker. <i>Journal of Virology</i> , 2004, 78, 5651-5657.	3.4	27
29	An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. <i>Vaccine</i> , 2012, 30, 922-930.	3.8	27
30	Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. <i>Glycobiology</i> , 2015, 25, 412-419.	2.5	27
31	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. <i>Journal of Infectious Diseases</i> , 2022, 226, 983-994.	4.0	26
32	Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2007, 81, 8533-8542.	3.4	25
33	The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions. <i>Journal of Virology</i> , 2009, 83, 1649-1659.	3.4	24
34	Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope Spike. <i>Journal of the American Chemical Society</i> , 2019, 141, 7946-7954.	13.7	19
35	Chemical and antigenic structure of the O-polysaccharide of the lipopolysaccharides from two <i>Acinetobacter haemolyticus</i> strains differing only in the anomeric configuration of one glycosyl residue in their O-antigens. <i>FEBS Journal</i> , 1999, 263, 587-595.	0.2	18
36	2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies. <i>Journal of Virology</i> , 2013, 87, 2234-2241.	3.4	18

#	ARTICLE	IF	CITATIONS
37	Synthesis of a Pentasaccharide Fragment Related to the Inner Core Region of Rhizobial and Agrobacterial Lipopolysaccharides. <i>Journal of Organic Chemistry</i> , 2017, 82, 12346-12358.	3.2	18
38	Antibody Epitope Exposure and Neutralization of HIV-1. <i>Current Pharmaceutical Design</i> , 2010, 16, 3729-3743.	1.9	17
39	Comparative Antigenicity of Thiourea and Adipic Amide Linked Neoglycoconjugates Containing Modified Oligomannose Epitopes for the Carbohydrate-Specific anti-HIV Antibody 2G12. <i>Bioconjugate Chemistry</i> , 2019, 30, 70-82.	3.6	15
40	Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. <i>PLoS ONE</i> , 2015, 10, e0125575.	2.5	13
41	Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies. <i>Scientific Reports</i> , 2020, 10, 7582.	3.3	11
42	Use of a Murine O-Antigen-Specific Monoclonal Antibody To Identify <i>Acinetobacter</i> Strains of Unnamed Genomic Species 13 Sensu Tjernberg and Ursing. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1693-1698.	3.9	11
43	Effect of buffer composition on PNA-RNA hybridization studied in the microfluidic microarray chip. <i>Canadian Journal of Chemistry</i> , 2018, 96, 241-247.	1.1	10
44	Identification of <i>Acinetobacter</i> Isolates from Species Belonging to the <i>Acinetobacter calcoaceticus</i> - <i>Acinetobacter baumannii</i> Complex with Monoclonal Antibodies Specific for O Antigens of Their Lipopolysaccharides. <i>Vaccine Journal</i> , 2002, 9, 60-65.	3.1	9
45	Generation and Serological Characterization of Murine Monoclonal Antibodies against O Antigens from <i>Acinetobacter</i> Reference Strains. <i>Vaccine Journal</i> , 2001, 8, 825-827.	2.6	5
46	HIV-1 Entry and Prospects for Protecting against Infection. <i>Microorganisms</i> , 2021, 9, 228.	3.6	5
47	A glycoside analog of mammalian oligomannose formulated with a TLR4-stimulating adjuvant elicits HIV-1 cross-reactive antibodies. <i>Scientific Reports</i> , 2021, 11, 4637.	3.3	3
48	Complex binding sites made to order. <i>Nature Biotechnology</i> , 2012, 30, 154-155.	17.5	1
49	The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. <i>Virology</i> , 2014, 462-463, 98-106.	2.4	1
50	Synthetic Neoglycoconjugates of Hepta- and Nonamannoside Ligands for Eliciting Oligomannose-Specific HIV-1 Neutralizing Antibodies. <i>ChemBioChem</i> , 2022, 23, .	2.6	0